Trial Profile
A Multicenter Randomised Phase II Study Comparing the Efficiency of a HT Concomitant With RT vs RT Alone in the Salvage of Patients With a Detectable PSA After Prostatectomy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 May 2022
Price :
$35
*
At a glance
- Drugs Degarelix (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms GETUG-AFU22
- 11 May 2022 Planned End Date changed from 1 Jun 2025 to 1 Mar 2025.
- 26 Jul 2020 Results assessing Late toxicity and quality of life from GETUG-AFU 22 study presented at the 35th Congress of the European Association of Urology
- 15 Feb 2020 Results of GETUG-AFU22 assessing Late toxicity and quality of life, presented at the 2020 Genitourinary Cancers Symposium.